MNOV.O (MNOV.O) News
Track canonical SquawkNews coverage tagged to MNOV.O, MNOV.O. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BRIEF — Medicinova Announces Completion Of Last Patient, Last Visit In The Double — Blind Portion Of The Phase 2B/3 Combat — Als Trial Of Mn — 166
Sept 24 (Reuters) — MediciNova Inc: Medicinova Announces Completion Of Last Patient, Last Visit In The Double-blind Portion Of The Phase 2b/3 Combat-als Trial Of Mn-166 (Ibudilast) Medicinova - Topline Results From Doubl
NEWS | Sep 24, 2026, 10:05 AM UTC
L
MediciNova completes last patient visit in COMBAT — ALS Phase 2b/3 trial of MN — 166 ibudilast
MediciNova completed the last patient, last visit in the double-blind portion of its COMBAT-ALS Phase 2b/3 trial of MN-166. Topline results have not been presented yet; release is expected by end-2026, with the full stud
NEWS | Sep 24, 2026, 10:01 AM UTC